Donna McLean, NP
Family · Greenville, NCNPI 1194700153
Payments from drug & device makers
Across 71 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$161
- Amarin Pharma, Inc.$139
- Novo Nordisk$106
- Insulet Corporation$94
- Otsuka Pharmaceutical Development & Commercialization, Inc.$84
- Biohaven Pharmaceutical Holding Company Ltd.$84
- plus $646 from 18 others
What the payments were for
- Food & beverage$1,314100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $161 |
| Amarin Pharma, Inc. | 9 | $139 |
| Novo Nordisk | 7 | $106 |
| Insulet Corporation | 4 | $94 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $84 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $84 |
| Lilly USA, LLC | 5 | $76 |
| Boston Scientific | 2 | $71 |
| Abbott | 3 | $69 |
| Teva Pharmaceuticals USA, Inc. | 4 | $58 |
| Genentech USA, Inc. | 2 | $44 |
| Dexcom, Inc. | 2 | $43 |
| Pfizer | 2 | $36 |
| Novartis | 2 | $33 |
| Currax Pharmaceuticals LLC | 2 | $32 |
| GSK | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $26 |
| Globus Medical | 1 | $26 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Medtronic | 1 | $21 |
| Mylan Specialty L.p. | 1 | $19 |
| Eisai Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| AstraZeneca | 1 | $11 |
How this compares
$1,314 in reported general payments places this provider in the 75th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 135 | $5,120 |
| Lacosamide | 31 | $5,023 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 111 | $3,033 |
| Oxcarbazepine | 29 | $2,389 |
| Memantine Hcl | 56 | $1,670 |
| Gabapentin | 84 | $1,406 |
| Lamotrigine | 48 | $1,356 |
| Primidone | 73 | $1,313 |
| Donepezil Hcl | 154 | $1,262 |
| Carbamazepine | 11 | $1,143 |
| Quetiapine Fumarate | 49 | $594 |
| Nortriptyline Hcl | 26 | $526 |
| Propranolol Hcl | 36 | $502 |
| RivastigmineRivastigmine Tartrate | 13 | $477 |
| Carbamazepine ErCarbamazepine | 15 | $466 |
Paid to pharmacies, not to this prescriber.
Other family in Greenville
- Jacob HinesGreenville$53K
- Phillip CovingtonGreenville$15K
- Melissa OttGreenville$13K
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.